For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Vistagen Therapeutics Inc’s stock clocked out at $0.68, up 2.58% from its previous closing price of $0.66. In other words, the price has increased by $2.58 from its previous closing price. On the day, 1.94 million shares were traded. VTGN stock price reached its highest trading level at $0.7032 during the session, while it also had its lowest trading level at $0.6362.
Ratios:
To gain a deeper understanding of VTGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 5.79. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On December 17, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $1.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTGN now has a Market Capitalization of 26817412 and an Enterprise Value of -48492588. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.31 while its Price-to-Book (P/B) ratio in mrq is 0.40. Its current Enterprise Value per Revenue stands at -67.257 whereas that against EBITDA is 0.743.
Stock Price History:
The Beta on a monthly basis for VTGN is 0.30, which has changed by -0.7875 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, VTGN has reached a high of $5.14, while it has fallen to a 52-week low of $0.63. The 50-Day Moving Average of the stock is -80.29%, while the 200-Day Moving Average is calculated to be -76.91%.
Shares Statistics:
It appears that VTGN traded 2.38M shares on average per day over the past three months and 4245180 shares per day over the past ten days. A total of 38.89M shares are outstanding, with a floating share count of 33.66M. Insiders hold about 14.78% of the company’s shares, while institutions hold 44.98% stake in the company. Shares short for VTGN as of 1765756800 were 1791894 with a Short Ratio of 0.75, compared to 1763078400 on 1517368. Therefore, it implies a Short% of Shares Outstanding of 1791894 and a Short% of Float of 6.4799999999999995.
Earnings Estimates
. The current assessment of Vistagen Therapeutics Inc (VTGN) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.2 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.73 and -$1.99 for the fiscal current year, implying an average EPS of -$1.83. EPS for the following year is -$1.23, with 4.0 analysts recommending between -$0.8 and -$1.69.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for VTGN’s current fiscal year. The highest revenue estimate was $1.4M, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $884k. In the same quarter a year ago, actual revenue was $486k
